Suppression of Aromatase Activity in Polycystic Ovary Syndrome
Polycystic ovary syndrome (PCOS) is the most common reproductive endocrine disorder in women of childbearing age. Estimates of incidence based on ultrasound scans of normal populations suggest that up to 23% of normal women may have polycystic ovaries (1); however, not all of these women are anovulatory or require medical treatment. The majority of the women with ultrasound evidence of PCOS have irregular menstrual cycles (75%) and 75% of the women with regular cycles are hirsute. This is in contrast to the women with normal ovaries (no ultrasound evidence of polycystic ovaries) of whom only.9% have irregular cycles (2). Within the infertile population, approximately three quarters of women with anovulatory infertility have PCO, thus accounting for approximately one third of women with secondary amenorrhea and approximately 90% of women with oligomenorrhea (3). Clearly PCOS affects a large number of women and is associated with menstrual irregularities in a large proportion of women.
KeywordsCholesterol Estrogen Testosterone Androgen Estradiol
Unable to display preview. Download preview PDF.
- 9.Erickson GF. Polycystic ovary syndrome: normal and abnormal steroidogenesis. In: Schats R, Schoemaker J, eds. Ovarian endocrinopathies. London: Parthenon Publishing, 1994: 103–15.Google Scholar
- 10.Zeleznik AJ, Fairchild-Benyo D. Control of follicular development, corpus luteum function, and the recognition of pregnancy in higher primates. In: Knobil E, Neill JD, eds. The physiology of reproduction. New York: Raven Press, 1994: 751–82.Google Scholar
- 12.Hedin L, Rodgers RJ, Simpson ER, Richards JS. Changes in content of cytochrome P45017α, cytochrome P450ssc, and 3-hydroxy-3-methylglutary CoA reductase in developing rat ovarian follicles and corpora lutea: correlation with theca cell steroidogenesis. Biol Reprod 1987; 37: 211–23.PubMedCrossRefGoogle Scholar
- 14.Gelety TJ, Magoffin DA. Ontogeny of steroidogenic enzyme gene expression in the theca interna of developing ovarian follicles. In: Society for Gynecologic Investigation, 1994, Abstract 125.Google Scholar
- 27.Pache TD, Hop WCJ, De Jong FH, Leerentveld RA, van Geldorp H, Van de Kamp TMM, Gooren LJG, Fauser BCJM. 17β-oestradiol, androstenedione and inhibin levels in fluid from individual follicles of normal and polycystic ovaries, and in ovaries from androgen treated female to male transsexuals. Clin Endocrinol 1992; 36: 565–71.CrossRefGoogle Scholar
- 28.Lambert-Messerlain GM, Hall JE, Sluss PM, Taylor AE, Martin KA, Groome NP, Crowley WF, Schneyer AL. Relatively low levels of dimeric inhibin circulate in men and women with polycystic ovarian syndrome using a specific two-site enzyme-linked immunosorbent assay. J Clin Endocrinol Metab 1994; 79: 45–50.CrossRefGoogle Scholar
- 29.Eden JA, Jones J, Carter GD, Alaghband-Zadeh J. Follicular fluid concentrations of insulin-like growth factor 1, epidermal growth factor, transforming growth factor-alpha and sex-steroids in volume matched normal and polycystic human follicles. Clin Endocrinol 1990; 32: 395–405.CrossRefGoogle Scholar
- 36.Volpe A, Coukos G, D’Ambrogio G, Artini PG, Genazzani AR. Follicular fluid steroid and epidermal growth factor content, and in vitro estrogen release by granulosa-luteal cells from patients with polycystic ovaries in an IVF/ET program. Eur J Obstet Gynecol Reprod Biol 1991; 42: 195–9.PubMedCrossRefGoogle Scholar
- 37.Agarwal SK, Judd HL, Magoffin DA. A mechanism for suppression of estrogen in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81: in press.Google Scholar
- 42.Hillier SG, van den Boogaard AM, Reichert LE, van Hall EV. Alterations in granulosa cell aromatase activity accompanying preovulatory follicular development in the rat ovary with evidence that 5alpha-reduced C19 steroids inhibit the aromatase reaction in vitro. J Endocrinol 1980; 84: 409–19.PubMedCrossRefGoogle Scholar